Drugs affect human life and health. Accordingly, in the various processes from drug manufacturing to their distribution and use, pharmaceutical companies are required to exercise quality control and post-marketing safety management by methods in compliance with the Ministerial Ordinance on Standards of Quality Assurance for Drugs, Quasi-drugs, Cosmetics and Medical Devices (GQP Ministerial Ordinance) and the Ministerial Ordinance on Standards for Post-Marketing Safety Control of Drugs, Quasi-drugs, Cosmetics, Medical Devices, and Regenerative Medicine Products (GVP Ministerial Ordinance) issued by the Ministry of Health, Labour and Welfare.
In Mochida Pharmaceutical Group, the RA, QA and PV divisions manage and evaluate the quality of products handled. These divisions also work on business activities related to the stable supply of drugs by, for example, ensuring appropriate manufacturing control and quality control and working to manage market shipments. Pharmacovigilance activities consisting of the collection and evaluation of information from a wide range of sources such as reports from medical institutions, information from scientific literature and societies is used to inform necessary measures. In addition to traditional aggregation and evaluation, our RA, QA and PV divisions have also started using medical information databases in their pharmacovigilance and safety evaluation activities. These divisions support business activities by ensuring the reliability of products through such quality and safety management activities.